Board summary
Key figures
27,894
Registered population
59.9% aged 18–64
19.0%
Aged 65+
ICB 18.8% · England 17.9%
17.6%
Ethnic minority (non-White)
6.3% Asian · England 9.6%
0.4%
In IMD quintile 1
ICB 0.8% · England 21.0%
~137
Core20 residents (est.)
Resident basis; registered basis ~147 · see page 3
5,527
Hypertension register
+5.78% in 3 yrs · England +5.60%
305
SMI register
33.2% of Tandridge's
566
COPD register
Reviews +0.28% in 3 yrs
Forecast to 2030
6,653
Hypertension patients, 2030
+1,126 on today
75.2%
QRISK ≥20% on statins, 2030
+5.49pp over 3 yrs
6.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
13 three-year trends trail England's pace.
SMI BMI checks fell 3.0 pp (England +5.1 pp) and BP checks fell 1.6 pp (England +4.4 pp), which may reflect unverified recall slippage.
Age-five MMR coverage drops between doses.
Age-five MMR1 reaches 95.0%, but MMR2 is 90.1% (6.4 pp lower at Warlingham Green Med Prac), which could reflect pre-school recall gaps.
Current cardiovascular and respiratory checks exceed England.
Hypertension treated to target is 73.8% (England 70.3%) and COPD annual reviews reach 83.9% (England 76.4%), showing strong current care-process delivery.
Population, age and ethnicity
Patients aged 65+ reach 19.0% alongside practice list discrepancies across three member practices
Registered patients aged 65+ represent 19.0% (5,311), below Tandridge (20.9%) but above NHS Surrey Heartlands Integrated Care Board (18.8%) and England (17.9%). Patients aged 0-17 account for 21.1% (5,877; Tandridge 20.4%, ICB 20.4%, England 19.6%). Census resident estimates (not registered patients) are 82.5% White (Tandridge 89.4%, ICB 85.3%, England 81.1%), 6.3% Asian, 5.3% Mixed and 4.6% Black. Practice lists total 38,613 versus the 27,894 PCN list, so denominators must be reconciled when planning capacity.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Tandridge local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tandridge LA) | 2,455 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.0% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tandridge LA) | 1,233 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tandridge LA) | 12.0 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 0.4% overall and concentrated at Warlingham Green Med Prac
The PCN records low overall deprivation, with an average IMD decile of 7.6 compared to 7.1 in Tandridge, 7.9 in the ICB and 5.5 in England. Only 0.4% of registered patients live in Core20 areas, below England (21.0%) and the ICB (0.8%; Tandridge 0.0%). Deprivation is concentrated at Warlingham Green Med Prac (0.7% share, 147 estimated patients), while Caterham Valley Medical Practice and Elizabeth House Medical Practice report 0.0%. Practice list sizes sum to 38,613 against the 27,894 PCN list. Targeted health inequality outreach can focus on the single practice.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
305
SMI register
0.80% recorded prevalence
200
Learning disability register
0.52% recorded prevalence
22
Care homes, 578 beds
In the PCN catchment
8.3%
Provide unpaid care
Tandridge, Census 2021
Recorded learning disability prevalence is 0.5% (200 patients), below Tandridge (0.7%) and England (0.6%), and matching NHS Surrey Heartlands Integrated Care Board (0.5%). Severe mental illness prevalence is 0.8% (305 patients), matching Tandridge (0.8%) and the ICB (0.8%), but below England (1.0%). The PCN catchment contains 22 care homes with 578 beds.
Severe mental illness: physical health checks
SMI BP checks reach 87.0% (England 83.4%) and BMI 85.3% (England 82.1%). Over three years, BP checks fell 1.6 pp (England +4.4 pp) and BMI fell 3.0 pp (England +5.1 pp), consistent with unverified recall slippage an audit could test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,527
Hypertension register
+5.78%
Register growth, 3 yrs
Tandridge +6.34% · England +5.60%
−0.97pp
BP control, under 80
≤140/90 · −1.08pp aged 80+
+1,126
More patients by 2030
Forecast 6,653 (16.23%)
Hypertension case-finding and control
Recorded hypertension prevalence is 14.5% (5,527 patients), below England (15.2%) and Tandridge (15.3%), but above NHS Surrey Heartlands ICB (14.3%); the register implies a 38,117 base against the 27,894 list. While 73.8% of patients are treated to target (England 70.3%) and 90.5% have a recent blood pressure check (England 90.0%), control fell 1.4% over three years (England +3.6%) and checks fell 0.7% (England +3.6%). Under-80 control also fell 1.3% (England +3.2%). Slower three-year progress may reflect recall slippage (unverified locally). Slipping control trends behind England indicate that maintaining blood pressure recall protocols should be prioritised to prevent further erosion of current achievement.
Lipids and statins
Among patients with QRISK ≥ 20%, lipid-lowering therapy reaches 62.6% (England 63.6%, Tandridge 58.5%, ICB 59.4%) following +9.6% three-year growth (England +6.2%). Statin uptake in diabetes (40+ without CVD) is 75.3% (England 73.2%). Lower high-risk lipid coverage than England indicates untreated QRISK patients warrant review.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 46,849 | £2.40 | £2.24 | £1.86 | £112,438 |
| Cardiovascular (all), 2025 | 61,357 | £4.45 | £4.74 | £3.33 | £273,039 |
In 2026, lipid-regulating drugs cost £2.40 per item across 46,849 items, above England (£1.86), Tandridge (£2.36) and the ICB (£2.24), representing £25,298 more than at England's unit cost. Unit costs may reflect formulary choices or case-mix rather than inefficiency. Higher unit costs warrant reviewing lipid-modifying formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+7.35%
Asthma reviews, PCN 3-yr change
+4.44%
Asthma reviews, England
+6.03%
Asthma prevalence, PCN
COPD prevalence is 1.5% (566 patients), below England (1.9%) but rising +15.5% over three years (England +2.6%), with reviews reaching 83.9% (England 76.4%). Asthma prevalence is 6.2% (2,221 patients; England 6.6%), and reviews reached 70.3% (England 65.7%), leaving about 660 patients unreviewed. Second-hand smoking status was recorded for 88.0% of asthma patients aged 6-19 (England 78.8%). Implied denominator differences (a 37,987 base) urge caution, though proactive recall could address unreviewed patients.
Cancer register and children's immunisation
Cancer register prevalence is 4.7% (1,786 patients), above England (3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage at 12 months is 95.8%, meeting the 95.0% target. MMR dose 1 at 24 months is 88.6% (6.4 pp below target). At age 5, MMR dose 1 reaches 95.0%, but MMR dose 2 is 4.9 pp lower at 90.1% and 4-in-1 booster coverage is 88.1% (6.9 pp below target).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, 61.4% of cancers with a known stage (2,955 of 4,810) across NHS Surrey Heartlands ICB were diagnosed at stage 1 or 2 (England 55.3%), trailing the 75.0% national ambition, with about 650 extra early-stage cases needed. Staging was known for 67.7% of cancers (4,810 of 7,106; England 67.0%), reflecting system pathways rather than PCN care. Locally, breast screening coverage is 68.4% (England 69.9%, ICB 71.2%) and rose +4.5% over three years (England +8.4%), lowest at Warlingham Green Med Prac (65.9%). Slower screening progress may reflect recall variation (unverified locally; a practice audit could test it).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Surrey and Sussex Healthcare NHS Trust achieved 70.0% on the 62-day cancer standard (target 85.0%), below England (71.2%), NHS Surrey and Sussex Integrated Care Board (71.5%) and King's College Hospital NHS Foundation Trust (70.1%), but above Croydon Health Services NHS Trust (69.9%). The trust met the 28-day faster diagnosis standard at 77.7% (standard 75.0%). Diagnostic 6-week waits reached 28.5% across all tests (England 23.1%, King's College Hospital NHS Foundation Trust 19.1%, Croydon Health Services NHS Trust 3.5%), with ultrasound at 32.3% and echocardiography at 43.8%. These provider metrics describe system context, not PCN performance.
| Pathways within standard (%) | Surrey and Sussex Healthcare | Croydon Health | King's College | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 83.22 | 80.68 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 99.06 | 96.68 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 69.88 | 70.15 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Croydon Health | King's College | England |
|---|---|---|---|---|
| MRI | 27.53 | 0.26 | 21.22 | 21.40 |
| CT | 18.49 | 7.69 | 22.60 | 9.92 |
| Echocardiography | 43.78 | 3.60 | 14.39 | 28.48 |
| Colonoscopy | 15.11 | 21.80 | 41.81 | 30.83 |
| Gastroscopy | 21.06 | 17.94 | 35.98 | 29.02 |
| All 15 DM01 tests | 28.50 | 3.51 | 19.15 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In provisional June 2026 data, Surrey recorded 109,530 community care contacts across 33,510 patients (66,060 activities), with adults aged 65+ accounting for 69.6% of contacts. Across NHS Surrey and Sussex Integrated Care Board, community contacts totaled 309,615 (316,320 activities). These experimental figures reflect broad resident service volumes rather than unique North Tandridge PCN activity.
Practice variation and patient experience
Practice phone access varies by 16.6 pp while overall experience exceeds England
In 2025/26, QOF clinical achievement reached 96.0% to 99.9% (England 97.1%). However, vaccination and immunisation achievement trailed England (55.2%), spanning 12.8 pp from Warlingham Green Med Prac (34.0%) to Caterham Valley Medical Practice (46.8%), while Elizabeth House Medical Practice recorded 36.1%. Overall personalised care adjustments were 4.6% to 7.2% (England 10.0%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Warlingham Green | 97 | 0.7 | 68.5% | 76.5% | 93.2% |
| Elizabeth House | 124 | 0.0 | 79.4% | 74.5% | 90.6% |
| Caterham Valley | 106 | 0.0 | 62.8% | 70.6% | 82.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 three-year trends trail England despite strong current clinical achievement
Across 25 measures, 13 trail England's three-year change (2023 to 2025). Severe mental illness BMI recording fell 3.0 pp (England +5.1 pp), blood pressure checks fell 1.6 pp (England +4.4 pp), and smoking cessation offers fell 3.4 pp (England +0.1 pp). Hypertension treated to target fell 1.4% (England +3.6%). Yet current achievement remains above England for SMI BMI (85.3% vs 82.1%), SMI blood pressure (87.0% vs 83.4%), smoking cessation (94.7% vs 94.2%), and hypertension control (73.8% vs 70.3%). This pattern could reflect recall slippage from high baselines, though this is unverified locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BMI record (SMI)
Dementia register
BP check (SMI)
Hypertension treated to target
Alcohol record (psychosis)
Diabetes statin (no CVD)
Diabetes statin (CVD)
QRISK statin treatment
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tandridge | Asset | PCN | Tandridge |
|---|---|---|---|---|---|
| Care homes (catchment) | 22 (578 beds) | n/a | Schools (catchment) | 50 | n/a |
| Children's centres | 3 | 6 | Places of worship | 32 | 61 |
| Libraries | 2 | 4 | Food banks (VCS) | 2 | 2 |
| Day centres (VCS) | n/a | 5 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 3 | Primary schools (LA maintained) | 5 | 14 |
| Primary academies | 8 | 11 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
SMI and hypertension recall audit
Thirteen of 25 measures trail England's 2023 to 2025 change: SMI BMI fell 3.0 pp (England +5.1 pp), SMI BP fell 1.6 pp (England +4.4 pp) and hypertension control fell 1.4% (England +3.6%). For discussion: audit SMI and hypertension recall lists, starting at Caterham Valley Medical Practice (80.8% SMI BP). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 2
Pre-school MMR2 and booster catch-up
At age 5 (Q1 2025/26, 101 children), MMR1 is 95.0% but MMR2 is 4.9 pp lower at 90.1% (6.4 pp difference at Warlingham Green Med Prac); 4-in-1 booster is 88.1% (below the 95.0% target by 6.9 pp). For discussion: run pre-school recall checks for second MMR and 4-in-1 booster doses. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Asthma review and lipid therapy
Asthma reviews reach 70.3% of 2,221 patients (England 65.7%), leaving about 660 unreviewed; QRISK ≥ 20% lipid therapy is 62.6% (England 63.6%) and 2026 lipid-modifying unit cost is £2.40 (£25,298 more than England's £1.86 across 46,849 items). For discussion: recall unreviewed asthma patients and review QRISK lipid-modifying prescribing. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult list reconciliation (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness recall audit (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation catch-up outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted breast screening recall outreach (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Practice telephony and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · SMI and hypertension recall audit (p12) | SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope · Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Pre-school MMR2 and booster catch-up (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Asthma review and lipid therapy (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
